Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer

1.

S.J. Szilvassy, The biology of hematopoietic stem cells. Arch. Med. Res. 34, 446–460 (2003). doi:10.1016/j.arcmed.2003.06.004 CrossRefPubMed

2.

A.W. Wognum, A.C. Eaves, T.E. Thomas, Identification and isolation of hematopoietic stem cells. Arch. Med. Res. 34, 461–475 (2003). doi:10.1016/j.arcmed.2003.09.008 CrossRefPubMed

3.

D.C. Taussig, F. Miraki-Moud, F. Anjos-Afonso, D.J. Pearce, K. Allen, C. Ridler, D. Lillington, H. Oakervee, J. Cavenagh, S.G. Agrawal, T.A. Lister, J.G. Gribben, D. Bonnet, Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112, 568–575 (2008). doi:10.1182/blood-2007-10-118331 CrossRefPubMed

4.

D.C. Taussig, J. Vargaftig, F. Miraki-Moud, E. Griessinger, K. Sharrock, T. Luke, D. Lillington, H. Oakervee, J. Cavenagh, S.G. Agrawal, T.A. Lister, J.G. Gribben, D. Bonnet, Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 115, 1976–1984 (2010). doi:10.1182/blood-2009-02-206565 CrossRefPubMedPubMedCentral

5.

S. Aref, O. Salama, Y. Al-Tonbary, M. Fouda, A. Menessy, M. El-Sherbiny, L and E selectins in acute myeloid leukemia: expression, clinical relevance and relation to patient outcome. Hematology 7, 83–87 (2002). doi:10.1080/10245330290028579 CrossRefPubMed

6.

A.J. Gentles, S.K. Plevritis, R. Majeti, A.A. Alizadeh, Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 304, 2706–2715 (2010). doi:10.1001/jama.2010.1862 CrossRefPubMedPubMedCentral

7.

F. Ishikawa, S. Yoshida, Y. Saito, A. Hijikata, H. Kitamura, S. Tanaka, R. Nakamura, T. Tanaka, H. Tomiyama, N. Saito, M. Fukata, T. Miyamoto, B. Lyons, K. Ohshima, N. Uchida, S. Taniguchi, O. Ohara, K. Akashi, M. Harada, L.D. Shultz, Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25, 1315–1321 (2007). doi:10.1038/nbt1350 CrossRefPubMed

8.

T. Holyoake, X. Jiang, C. Eaves, A. Eaves, Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94, 2056–2064 (1999)PubMed

9.

C. Zhao, A. Chen, C.H. Jamieson, M. Fereshteh, A. Abrahamsson, J. Blum, H.Y. Kwon, J. Kim, J.P. Chute, D. Rizzieri, M. Munchhof, T. VanArsdale, P.A. Beachy, T. Reya, Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776–779 (2009). doi:10.1038/nature07737 CrossRefPubMedPubMedCentral

10.

M.L. Guzman, C.F. Swiderski, D.S. Howard, B.A. Grimes, R.M. Rossi, S.J. Szilvassy, C.T. Jordan, Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. U. S. A. 99, 16220–16225 (2002). doi:10.1073/pnas.252462599 CrossRefPubMedPubMedCentral

11.

C.T. Jordan, D. Upchurch, S.J. Szilvassy, M.L. Guzman, D.S. Howard, A.L. Pettigrew, T. Meyerrose, R. Rossi, B. Grimes, D.A. Rizzieri, S.M. Luger, G.L. Phillips, The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777–1784 (2000)CrossRefPubMed

12.

N. Hosen, C.Y. Park, N. Tatsumi, Y. Oji, H. Sugiyama, M. Gramatzki, A.M. Krensky, I.L. Weissman, CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 104, 11008–11013 (2007). doi:10.1073/pnas.0704271104 CrossRefPubMedPubMedCentral

13.

R. Majeti, M.P. Chao, A.A. Alizadeh, W.W. Pang, S. Jaiswal, K.D. Gibbs Jr., N. van Rooijen, I.L. Weissman, CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286–299 (2009). doi:10.1016/j.cell.2009.05.045 CrossRefPubMedPubMedCentral

14.

Y. Kikushige, T. Shima, S. Takayanagi, S. Urata, T. Miyamoto, H. Iwasaki, K. Takenaka, T. Teshima, T. Tanaka, Y. Inagaki, K. Akashi, TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7, 708–717 (2010). doi:10.1016/j.stem.2010.11.014 CrossRefPubMed

15.

M.P. Scolnik, R. Morilla, M.M. de Bracco, D. Catovsky, E. Matutes, CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease. Leuk. Res. 26, 615–619 (2002)CrossRefPubMed

16.

A. Chavez-Gonzalez, E. Dorantes-Acosta, D. Moreno-Lorenzana, A. Alvarado-Moreno, L. Arriaga-Pizano, H. Mayani, Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia. Arch. Med. Res. 45, 343–350 (2014). doi:10.1016/j.arcmed.2014.04.001 CrossRefPubMed

17.

J.M. Gerber, B.D. Smith, B. Ngwang, H. Zhang, M.S. Vala, L. Morsberger, S. Galkin, M.I. Collector, B. Perkins, M.J. Levis, C.A. Griffin, S.J. Sharkis, M.J. Borowitz, J.E. Karp, R.J. Jones, A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 119, 3571–3577 (2012). doi:10.1182/blood-2011-06-364182 CrossRefPubMedPubMedCentral

18.

M. Jaras, P. Johnels, N. Hansen, H. Agerstam, P. Tsapogas, M. Rissler, C. Lassen, T. Olofsson, O.W. Bjerrum, J. Richter, T. Fioretos, Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc. Natl. Acad. Sci. U. S. A. 107, 16280–16285 (2010). doi:10.1073/pnas.1004408107 CrossRefPubMedPubMedCentral

19.

H. Herrmann, I. Sadovnik, S. Cerny-Reiterer, T. Rulicke, G. Stefanzl, M. Willmann, G. Hoermann, M. Bilban, K. Blatt, S. Herndlhofer, M. Mayerhofer, B. Streubel, W.R. Sperr, T.L. Holyoake, C. Mannhalter, P. Valent, Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood 123, 3951–3962 (2014). doi:10.1182/blood-2013-10-536078 CrossRefPubMed

20.

M.E. Chamuleau, G.J. Ossenkoppele, A. van Rhenen, L. van Dreunen, S.M. Jirka, A. Zevenbergen, G.J. Schuurhuis, A.A. van de Loosdrecht, High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk. Res. 35, 741–749 (2011). doi:10.1016/j.leukres.2010.12.032 CrossRefPubMed

21.

M. Terwijn, N. Feller, A. van Rhenen, A. Kelder, G. Westra, S. Zweegman, G. Ossenkoppele, G.J. Schuurhuis, Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur. J. Cancer 45, 1692–1699 (2009). doi:10.1016/j.ejca.2009.02.021 CrossRefPubMed

22.

M. Terwijn, W. Zeijlemaker, A. Kelder, A.P. Rutten, A.N. Snel, W.J. Scholten, T. Pabst, G. Verhoef, B. Lowenberg, S. Zweegman, G.J. Ossenkoppele, G.J. Schuurhuis, Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One 9, e107587 (2014). doi:10.1371/journal.pone.0107587 CrossRefPubMedPubMedCentral

23.

A.V. Krivtsov, D. Twomey, Z. Feng, M.C. Stubbs, Y. Wang, J. Faber, J.E. Levine, J. Wang, W.C. Hahn, D.G. Gilliland, T.R. Golub, S.A. Armstrong, Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818–822 (2006). doi:10.1038/nature04980 CrossRefPubMed

24.

L.I. Shlush, S. Zandi, A. Mitchell, W.C. Chen, J.M. Brandwein, V. Gupta, J.A. Kennedy, A.D. Schimmer, A.C. Schuh, K.W. Yee, J.L. McLeod, M. Doedens, J.J. Medeiros, R. Marke, H.J. Kim, K. Lee, J.D. McPherson, T.J. Hudson, A.M. Brown, F. Yousif, Q.M. Trinh, L.D. Stein, M.D. Minden, J.C. Wang, J.E. Dick, Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328–333 (2014). doi:10.1038/nature13038 CrossRefPubMedPubMedCentral

25.

M.R. Corces-Zimmerman, W.J. Hong, I.L. Weissman, B.C. Medeiros, R. Majeti, Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl. Acad. Sci. U. S. A. 111, 2548–2553 (2014). doi:10.1073/pnas.1324297111 CrossRefPubMedPubMedCentral

26.

S. Babashah, Cancer stem cells: emerging concepts and future perspectives in translational oncology (Springer International Publishing, Switzerland, 2015)CrossRef

27.

P.R. Hamann, L.M. Hinman, I. Hollander, C.F. Beyer, D. Lindh, R. Holcomb, W. Hallett, H.R. Tsou, J. Upeslacis, D. Shochat, A. Mountain, D.A. Flowers, I. Bernstein, Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13, 47–58 (2002)CrossRefPubMed

28.

A. Takeshita, Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia. Int. J. Hematol. 97, 703–716 (2013). doi:10.1007/s12185-013-1365-1 CrossRefPubMed

29.

A. Dutour, V. Marin, I. Pizzitola, S. Valsesia-Wittmann, D. Lee, E. Yvon, H. Finney, A. Lawson, M. Brenner, A. Biondi, E. Biagi, R. Rousseau, In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv. Hematol. 2012, 683065 (2012). doi:10.1155/2012/683065 CrossRefPubMedPubMedCentral

30.

I. Pizzitola, V. Agostoni, E. Cribioli, M. Pule, R. Rousseau, H. Finney, A. Lawson, A. Biondi, E. Biagi, V. Marin, In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy. J. Immunother. 34, 469–479 (2011). doi:10.1097/CJI.0b013e31821e763b CrossRefPubMed

31.

M. Feuring-Buske, A.E. Frankel, R.L. Alexander, B. Gerhard, D.E. Hogge, A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res. 62, 1730–1736 (2002)PubMed

32.

H.P. Kim, A.E. Frankel, D.E. Hogge, A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leuk. Res. 34, 1035–1042 (2010). doi:10.1016/j.leukres.2009.12.008 CrossRefPubMed

33.

L. Jin, E.M. Lee, H.S. Ramshaw, S.J. Busfield, A.G. Peoppl, L. Wilkinson, M.A. Guthridge, D. Thomas, E.F. Barry, A. Boyd, D.P. Gearing, G. Vairo, A.F. Lopez, J.E. Dick, R.B. Lock, Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5, 31–42 (2009). doi:10.1016/j.stem.2009.04.018 CrossRefPubMed

34.

S.J. Busfield, M. Biondo, M. Wong, H.S. Ramshaw, E.M. Lee, S. Ghosh, H. Braley, C. Panousis, A.W. Roberts, S.Z. He, D. Thomas, L. Fabri, G. Vairo, R.B. Lock, A.F. Lopez, A.D. Nash, Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia 28, 2213–2221 (2014). doi:10.1038/leu.2014.128 CrossRefPubMed

35.

I. Pizzitola, F. Anjos-Afonso, K. Rouault-Pierre, F. Lassailly, S. Tettamanti, O. Spinelli, A. Biondi, E. Biagi, D. Bonnet, Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 28, 1596–1605 (2014). doi:10.1038/leu.2014.62 CrossRefPubMed

36.

S. Gill, S.K. Tasian, M. Ruella, O. Shestova, Y. Li, D.L. Porter, M. Carroll, G. Danet-Desnoyers, J. Scholler, S.A. Grupp, C.H. June, M. Kalos, Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123, 2343–2354 (2014). doi:10.1182/blood-2013-09-529537 CrossRefPubMedPubMedCentral

37.

Z. Gadhoum, J. Delaunay, E. Maquarre, L. Durand, V. Lancereaux, J. Qi, J. Robert-Lezenes, C. Chomienne, F. Smadja-Joffe, The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk. Lymphoma 45, 1501–1510 (2004). doi:10.1080/1042819042000206687 CrossRefPubMed

38.

G. Song, X. Liao, L. Zhou, L. Wu, Y. Feng, Z.C. Han, HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leuk. Res. 28, 1089–1096 (2004). doi:10.1016/j.leukres.2004.02.005 CrossRefPubMed

39.

L. Jin, K.J. Hope, Q. Zhai, F. Smadja-Joffe, J.E. Dick, Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12, 1167–1174 (2006). doi:10.1038/nm1483 CrossRefPubMed

40.

J.L. Berkowitz, J.E. Janik, D.M. Stewart, E.S. Jaffe, M. Stetler-Stevenson, J.H. Shih, T.A. Fleisher, M. Turner, N.E. Urquhart, G.H. Wharfe, W.D. Figg, C.J. Peer, C.K. Goldman, T.A. Waldmann, J.C. Morris, Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin. Immunol. 155, 176–187 (2014). doi:10.1016/j.clim.2014.09.012 CrossRefPubMedPubMedCentral

41.

J. Cerny, H. Yu, M. Ramanathan, G.D. Raffel, W.V. Walsh, N. Fortier, L. Shanahan, E. O’Rourke, J. Bednarik, B. Barton, A. Kroll-Desrosiers, S. Hao, B. Woda, L. Hutchinson, A.M. Evens, A.G. Rosmarin, R. Nath, Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). Br. J. Haematol. 160, 262–266 (2013). doi:10.1111/bjh.12109 CrossRefPubMed

42.

G.J.R. J. N. Allan, E. J. Feldman, J. M. Scandura, E. K. Ritchie, L. Lam, W. Xie, H-T Hsu, D. C. Hassane, M. L. Guzman, In 56th ASH Annual Meeting and Exposition, (San Francisco, CA) (2014)

43.

Z. Guo, A. Wang, W. Zhang, M. Levit, Q. Gao, C. Barberis, M. Tabart, J. Zhang, D. Hoffmann, D. Wiederschain, J. Rocnik, F. Sun, J. Murtie, C. Lengauer, S. Gross, B. Zhang, H. Cheng, V. Patel, L. Schio, F. Adrian, M. Dorsch, C. Garcia-Echeverria, S.M. Huang, PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene. Blood 124, 1777–1789 (2014). doi:10.1182/blood-2014-01-551234 CrossRefPubMed

44.

X. Zhao, S. Singh, C. Pardoux, J. Zhao, E.D. Hsi, A. Abo, W. Korver, Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 95, 71–78 (2010). doi:10.3324/haematol.2009.009811 CrossRefPubMed

45.

H. Lu, Q. Zhou, V. Deshmukh, H. Phull, J. Ma, V. Tardif, R.R. Naik, C. Bouvard, Y. Zhang, S. Choi, B.R. Lawson, S. Zhu, C.H. Kim, P.G. Schultz, Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew. Chem. Int. Ed. Engl. 53, 9841–9845 (2014). doi:10.1002/anie.201405353 CrossRefPubMedPubMedCentral

46.

M. Askmyr, H. Agerstam, N. Hansen, S. Gordon, A. Arvanitakis, M. Rissler, G. Juliusson, J. Richter, M. Jaras, T. Fioretos, Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 121, 3709–3713 (2013). doi:10.1182/blood-2012-09-458935 CrossRefPubMed

47.

D.E. Berardi, C. Flumian, P.B. Campodonico, A.J. Urtreger, M.I. Diaz Bessone, A.N. Motter, E.D. Bal de Kier Joffe, E.F. Farias, L.B. Todaro, Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid. Cell. Oncol. 38, 289–305 (2015). doi:10.1007/s13402-015-0230-z CrossRef

48.

A. Kakizuka, W.H. Miller Jr., K. Umesono, R.P. Warrell Jr., S.R. Frankel, V.V. Murty, E. Dmitrovsky, R.M. Evans, Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66, 663–674 (1991)CrossRefPubMed

49.

P.V. Sanchez, S.T. Glantz, S. Scotland, M.T. Kasner, M. Carroll, Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors. Leukemia 28, 749–760 (2014). doi:10.1038/leu.2013.202 CrossRefPubMed

50.

S. Grant, ATRA and ATO team up against NPM1. Blood 125, 3369–3371 (2015). doi:10.1182/blood-2015-04-636217 CrossRefPubMed

51.

H. El Hajj, Z. Dassouki, C. Berthier, E. Raffoux, L. Ades, O. Legrand, R. Hleihel, U. Sahin, N. Tawil, A. Salameh, K. Zibara, N. Darwiche, M. Mohty, H. Dombret, P. Fenaux, H. de The, A. Bazarbachi, Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood 125, 3447–3454 (2015). doi:10.1182/blood-2014-11-612416 CrossRefPubMed

52.

X. Zheng, A. Seshire, B. Ruster, G. Bug, T. Beissert, E. Puccetti, D. Hoelzer, R. Henschler, M. Ruthardt, Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 92, 323–331 (2007)CrossRefPubMed

53.

Y. Jiang, Z.H. Xue, W.Z. Shen, K.M. Du, H. Yan, Y. Yu, Z.G. Peng, M.G. Song, J.H. Tong, Z. Chen, Y. Huang, M. Lubbert, G.Q. Chen, Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia 19, 1239–1247 (2005). doi:10.1038/sj.leu.2403734 CrossRefPubMed

54.

M. Roth, B. Will, G. Simkin, S. Narayanagari, L. Barreyro, B. Bartholdy, R. Tamari, C.S. Mitsiades, A. Verma, U. Steidl, Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 120, 386–394 (2012). doi:10.1182/blood-2011-12-399667 CrossRefPubMedPubMedCentral

55.

M. Szwed, A. Laroche-Clary, J. Robert, Z. Jozwiak, Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation. Cell. Oncol. 39, 107–118 (2016). doi:10.1007/s13402-015-0256-2 CrossRef

56.

J. Liu, X. Wei, Y. Wu, Y. Wang, Y. Qiu, J. Shi, H. Zhou, Z. Lu, M. Shao, L. Yu, L. Tong, Giganteaside D induces ROS-mediated apoptosis in human hepatocellular carcinoma cells through the MAPK pathway. Cell. Oncol. 39, 333–342 (2016). doi:10.1007/s13402-016-0273-9 CrossRef

57.

T.T. Vo, J. Ryan, R. Carrasco, D. Neuberg, D.J. Rossi, R.M. Stone, D.J. Deangelo, M.G. Frattini, A. Letai, Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151, 344–355 (2012). doi:10.1016/j.cell.2012.08.038 CrossRefPubMedPubMedCentral

58.

D.J. Goff, A. Court Recart, A. Sadarangani, H.J. Chun, C.L. Barrett, M. Krajewska, H. Leu, J. Low-Marchelli, W. Ma, A.Y. Shih, J. Wei, D. Zhai, I. Geron, M. Pu, L. Bao, R. Chuang, L. Balaian, J. Gotlib, M. Minden, G. Martinelli, J. Rusert, K.H. Dao, K. Shazand, P. Wentworth, K.M. Smith, C.A. Jamieson, S.R. Morris, K. Messer, L.S. Goldstein, T.J. Hudson, M. Marra, K.A. Frazer, M. Pellecchia, J.C. Reed, C.H. Jamieson, A pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 12, 316–328 (2013). doi:10.1016/j.stem.2012.12.011 CrossRefPubMedPubMedCentral

59.

A.S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M.W. Deininger, B.J. Druker, Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396–409 (2011). doi:10.1172/JCI35721 CrossRefPubMed

60.

M. Konopleva, M. Milella, P. Ruvolo, J.C. Watts, M.R. Ricciardi, B. Korchin, T. McQueen, W. Bornmann, T. Tsao, P. Bergamo, D.H. Mak, W. Chen, J. McCubrey, A. Tafuri, M. Andreeff, MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 26, 778–787 (2012). doi:10.1038/leu.2011.287 CrossRefPubMed

61.

M. Rahmani, M.M. Aust, E. Attkisson, D.C. Williams Jr., A. Ferreira-Gonzalez, S. Grant, Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 119, 6089–6098 (2012). doi:10.1182/blood-2011-09-378141 CrossRefPubMedPubMedCentral

62.

M. Skrtic, S. Sriskanthadevan, B. Jhas, M. Gebbia, X. Wang, Z. Wang, R. Hurren, Y. Jitkova, M. Gronda, N. Maclean, C.K. Lai, Y. Eberhard, J. Bartoszko, P. Spagnuolo, A.C. Rutledge, A. Datti, T. Ketela, J. Moffat, B.H. Robinson, J.H. Cameron, J. Wrana, C.J. Eaves, M.D. Minden, J.C. Wang, J.E. Dick, K. Humphries, C. Nislow, G. Giaever, A.D. Schimmer, Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20, 674–688 (2011). doi:10.1016/j.ccr.2011.10.015 CrossRefPubMedPubMedCentral

63.

Y. Jitkova, M. Gronda, R. Hurren, X. Wang, C.A. Goard, B. Jhas, A.D. Schimmer, A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. PLoS One 9, e95281 (2014). doi:10.1371/journal.pone.0095281 CrossRefPubMedPubMedCentral

64.

K. Goetze, C.G. Fabian, A. Siebers, L. Binz, D. Faber, S. Indraccolo, G. Nardo, U.G. Sattler, W. Mueller-Klieser, Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system. Cell. Oncol. (Dordr) 38, 377–385 (2015). doi:10.1007/s13402-015-0237-5 CrossRef

65.

Y.H. Wang, W.J. Israelsen, D. Lee, V.W. Yu, N.T. Jeanson, C.B. Clish, L.C. Cantley, M.G. Vander Heiden, D.T. Scadden, Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell 158, 1309–1323 (2014). doi:10.1016/j.cell.2014.07.048 CrossRefPubMedPubMedCentral

66.

D. Anastasiou, Y. Yu, W.J. Israelsen, J.K. Jiang, M.B. Boxer, B.S. Hong, W. Tempel, S. Dimov, M. Shen, A. Jha, H. Yang, K.R. Mattaini, C.M. Metallo, B.P. Fiske, K.D. Courtney, S. Malstrom, T.M. Khan, C. Kung, A.P. Skoumbourdis, H. Veith, N. Southall, M.J. Walsh, K.R. Brimacombe, W. Leister, S.Y. Lunt, Z.R. Johnson, K.E. Yen, K. Kunii, S.M. Davidson, H.R. Christofk, C.P. Austin, J. Inglese, M.H. Harris, J.M. Asara, G. Stephanopoulos, F.G. Salituro, S. Jin, L. Dang, D.S. Auld, H.W. Park, L.C. Cantley, C.J. Thomas, M.G. Vander Heiden, Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8, 839–847 (2012). doi:10.1038/nchembio.1060 CrossRefPubMedPubMedCentral

67.

K.M. Parnell, J.M. Foulks, R.N. Nix, A. Clifford, J. Bullough, B. Luo, A. Senina, D. Vollmer, J. Liu, V. McCarthy, Y. Xu, M. Saunders, X.H. Liu, S. Pearce, K. Wright, M. O’Reilly, M.V. McCullar, K.K. Ho, S.B. Kanner, Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol. Cancer Ther. 12, 1453–1460 (2013). doi:10.1158/1535-7163.MCT-13-0026 CrossRefPubMed

68.

T. Hitosugi, S. Kang, M.G. Vander Heiden, T.W. Chung, S. Elf, K. Lythgoe, S. Dong, S. Lonial, X. Wang, G.Z. Chen, J. Xie, T.L. Gu, R.D. Polakiewicz, J.L. Roesel, T.J. Boggon, F.R. Khuri, D.G. Gilliland, L.C. Cantley, J. Kaufman, J. Chen, Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2, ra73 (2009). doi:10.1126/scisignal.2000431 CrossRefPubMedPubMedCentral

69.

E.M. Sturgill, M.L. Guzman, In Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, (San Diego, CA) (2014)

70.

A. Ferraro, Altered primary chromatin structures and their implications in cancer development. Cell. Oncol. 39, 195–210 (2016). doi:10.1007/s13402-016-0276-6 CrossRef

71.

J. Yamazaki, M.R. Estecio, Y. Lu, H. Long, G.G. Malouf, D. Graber, Y. Huo, L. Ramagli, S. Liang, S.M. Kornblau, J. Jelinek, J.P. Issa, The epigenome of AML stem and progenitor cells. Epigenetics 8, 92–104 (2013). doi:10.4161/epi.23243 CrossRefPubMedPubMedCentral

72.

E.D. Lagadinou, A. Sach, K. Callahan, R.M. Rossi, S.J. Neering, M. Minhajuddin, J.M. Ashton, S. Pei, V. Grose, K.M. O’Dwyer, J.L. Liesveld, P.S. Brookes, M.W. Becker, C.T. Jordan, BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329–341 (2013). doi:10.1016/j.stem.2012.12.013 CrossRefPubMedPubMedCentral

73.

C. Craddock, L. Quek, N. Goardon, S. Freeman, S. Siddique, M. Raghavan, A. Aztberger, A. Schuh, D. Grimwade, A. Ivey, P. Virgo, R. Hills, T. McSkeane, J. Arrazi, S. Knapper, C. Brookes, B. Davies, A. Price, K. Wall, M. Griffiths, J. Cavenagh, R. Majeti, I. Weissman, A. Burnett, P. Vyas, Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 27, 1028–1036 (2013). doi:10.1038/leu.2012.312 CrossRefPubMed

74.

M.J. Chang, H. Wu, N.J. Achille, M.R. Reisenauer, C.W. Chou, N.J. Zeleznik-Le, C.S. Hemenway, W. Zhang, Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 70, 10234–10242 (2010). doi:10.1158/0008-5472.CAN-10-3294 CrossRefPubMedPubMedCentral

75.

P. Jo, K. Jung, M. Grade, L.C. Conradi, H.A. Wolff, J. Kitz, H. Becker, J. Ruschoff, A. Hartmann, T. Beissbarth, A. Muller-Dornieden, M. Ghadimi, R. Schneider-Stock, J. Gaedcke, CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Surgery 151, 564–570 (2012). doi:10.1016/j.surg.2011.08.013 CrossRefPubMed

76.

K.M. Bernt, N. Zhu, A.U. Sinha, S. Vempati, J. Faber, A.V. Krivtsov, Z. Feng, N. Punt, A. Daigle, L. Bullinger, R.M. Pollock, V.M. Richon, A.L. Kung, S.A. Armstrong, MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66–78 (2011). doi:10.1016/j.ccr.2011.06.010 CrossRefPubMedPubMedCentral

77.

T. Schenk, W.C. Chen, S. Gollner, L. Howell, L. Jin, K. Hebestreit, H.U. Klein, A.C. Popescu, A. Burnett, K. Mills, R.A. Casero Jr., L. Marton, P. Woster, M.D. Minden, M. Dugas, J.C. Wang, J.E. Dick, C. Muller-Tidow, K. Petrie, A. Zelent, Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18, 605–611 (2012). doi:10.1038/nm.2661 CrossRefPubMedPubMedCentral

78.

S.R. Daigle, E.J. Olhava, C.A. Therkelsen, C.R. Majer, C.J. Sneeringer, J. Song, L.D. Johnston, M.P. Scott, J.J. Smith, Y. Xiao, L. Jin, K.W. Kuntz, R. Chesworth, M.P. Moyer, K.M. Bernt, J.C. Tseng, A.L. Kung, S.A. Armstrong, R.A. Copeland, V.M. Richon, R.M. Pollock, Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53–65 (2011). doi:10.1016/j.ccr.2011.06.009 CrossRefPubMedPubMedCentral

79.

I. Maillard, J.L. Hess, The role of menin in hematopoiesis. Adv. Exp. Med. Biol. 668, 51–57 (2009)CrossRefPubMedPubMedCentral

80.

D.P. Mould, A.E. McGonagle, D.H. Wiseman, E.L. Williams, A.M. Jordan, Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date. Med. Res. Rev. 35, 586–618 (2014). doi:10.1002/med.21334 CrossRefPubMed

81.

W. Fiskus, Y. Wang, A. Sreekumar, K.M. Buckley, H. Shi, A. Jillella, C. Ustun, R. Rao, P. Fernandez, J. Chen, R. Balusu, S. Koul, P. Atadja, V.E. Marquez, K.N. Bhalla, Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114, 2733–2743 (2009). doi:10.1182/blood-2009-03-213496 CrossRefPubMedPubMedCentral

82.

J. Zhou, C. Bi, L.L. Cheong, S. Mahara, S.C. Liu, K.G. Tay, T.L. Koh, Q. Yu, W.J. Chng, The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118, 2830–2839 (2011). doi:10.1182/blood-2010-07-294827 CrossRefPubMed

83.

A. Chaturvedi, M.M. Araujo Cruz, N. Jyotsana, A. Sharma, H. Yun, K. Gorlich, M. Wichmann, A. Schwarzer, M. Preller, F. Thol, J. Meyer, R. Haemmerle, E.A. Struys, E.E. Jansen, U. Modlich, Z. Li, L.M. Sly, R. Geffers, R. Lindner, D.J. Manstein, U. Lehmann, J. Krauter, A. Ganser, M. Heuser, Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 122, 2877–2887 (2013). doi:10.1182/blood-2013-03-491571 CrossRefPubMed

84.

M.E. Figueroa, S. Lugthart, Y. Li, C. Erpelinck-Verschueren, X. Deng, P.J. Christos, E. Schifano, J. Booth, W. van Putten, L. Skrabanek, F. Campagne, M. Mazumdar, J.M. Greally, P.J. Valk, B. Lowenberg, R. Delwel, A. Melnick, DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13–27 (2010). doi:10.1016/j.ccr.2009.11.020 CrossRefPubMedPubMedCentral

85.

O. Abdel-Wahab, R.L. Levine, Metabolism and the leukemic stem cell. J. Exp. Med. 207, 677–680 (2010). doi:10.1084/jem.20100523 CrossRefPubMedPubMedCentral

86.

C. Frelin, V. Imbert, E. Griessinger, A.C. Peyron, N. Rochet, P. Philip, C. Dageville, A. Sirvent, M. Hummelsberger, E. Berard, M. Dreano, N. Sirvent, J.F. Peyron, Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 105, 804–811 (2005). doi:10.1182/blood-2004-04-1463 CrossRefPubMed

87.

K. Vazquez-Santillan, J. Melendez-Zajgla, L. Jimenez-Hernandez, G. Martinez-Ruiz, V. Maldonado, NF-kappaB signaling in cancer stem cells: a promising therapeutic target? Cell. Oncol. 38, 327–339 (2015). doi:10.1007/s13402-015-0236-6 CrossRef

88.

M.L. Guzman, S.J. Neering, D. Upchurch, B. Grimes, D.S. Howard, D.A. Rizzieri, S.M. Luger, C.T. Jordan, Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301–2307 (2001)CrossRefPubMed

89.

Y. Kagoya, A. Yoshimi, K. Kataoka, M. Nakagawa, K. Kumano, S. Arai, H. Kobayashi, T. Saito, Y. Iwakura, M. Kurokawa, Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. J. Clin. Invest. 124, 528–542 (2014). doi:10.1172/JCI68101 CrossRefPubMedPubMedCentral

90.

M.L. Guzman, R.M. Rossi, L. Karnischky, X. Li, D.R. Peterson, D.S. Howard, C.T. Jordan, The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105, 4163–4169 (2005). doi:10.1182/blood-2004-10-4135 CrossRefPubMedPubMedCentral

91.

P. Diamanti, C.V. Cox, J.P. Moppett, A. Blair, Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia. Blood 121, 1384–1393 (2013). doi:10.1182/blood-2012-08-448852 CrossRefPubMed

92.

M.L. Guzman, R.M. Rossi, S. Neelakantan, X. Li, C.A. Corbett, D.C. Hassane, M.W. Becker, J.M. Bennett, E. Sullivan, J.L. Lachowicz, A. Vaughan, C.J. Sweeney, W. Matthews, M. Carroll, J.L. Liesveld, P.A. Crooks, C.T. Jordan, An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110, 4427–4435 (2007). doi:10.1182/blood-2007-05-090621 CrossRefPubMedPubMedCentral

93.

D.C. Hassane, M.L. Guzman, C. Corbett, X. Li, R. Abboud, F. Young, J.L. Liesveld, M. Carroll, C.T. Jordan, Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 111, 5654–5662 (2008). doi:10.1182/blood-2007-11-126003 CrossRefPubMedPubMedCentral

94.

M.L. Guzman, N. Yang, K.K. Sharma, M. Balys, C.A. Corbett, C.T. Jordan, M.W. Becker, U. Steidl, O. Abdel-Wahab, R.L. Levine, G. Marcucci, G.J. Roboz, D.C. Hassane, Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Mol. Cancer Ther. 13, 1979–1990 (2014). doi:10.1158/1535-7163.MCT-13-0963 CrossRefPubMedPubMedCentral

95.

N. Lounnas, C. Frelin, N. Gonthier, P. Colosetti, A. Sirvent, J.P. Cassuto, F. Berthier, N. Sirvent, P. Rousselot, M. Dreano, J.F. Peyron, V. Imbert, NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. Int. J. Cancer 125, 308–317 (2009). doi:10.1002/ijc.24294 CrossRefPubMed

96.

S.K. Tasian, D.T. Teachey, S.R. Rheingold, Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Front. Oncol. 4, 108 (2014). doi:10.3389/fonc.2014.00108 PubMedPubMedCentral

97.

T. Skorski, P. Kanakaraj, M. Nieborowska-Skorska, M.Z. Ratajczak, S.C. Wen, G. Zon, A.M. Gewirtz, B. Perussia, B. Calabretta, Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86, 726–736 (1995)PubMed

98.

C. Billottet, V.L. Grandage, R.E. Gale, A. Quattropani, C. Rommel, B. Vanhaesebroeck, A. Khwaja, A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25, 6648–6659 (2006). doi:10.1038/sj.onc.1209670 CrossRefPubMed

99.

A.M. Martelli, C. Evangelisti, F. Chiarini, J.A. McCubrey, The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 1, 89–103 (2010)CrossRefPubMedPubMedCentral

100.

P.L. Tazzari, A. Cappellini, F. Ricci, C. Evangelisti, V. Papa, T. Grafone, G. Martinelli, R. Conte, L. Cocco, J.A. McCubrey, A.M. Martelli, Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21, 427–438 (2007). doi:10.1038/sj.leu.2404523 CrossRefPubMed

101.

E. Pastwa, T. Poplawski, U. Lewandowska, S.B. Somiari, J. Blasiak, R.I. Somiari, Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells. Int. J. Biochem. Cell Biol. 53, 423–431 (2014). doi:10.1016/j.biocel.2014.06.007 CrossRefPubMed

102.

V. Papa, P.L. Tazzari, F. Chiarini, A. Cappellini, F. Ricci, A.M. Billi, C. Evangelisti, E. Ottaviani, G. Martinelli, N. Testoni, J.A. McCubrey, A.M. Martelli, Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 22, 147–160 (2008). doi:10.1038/sj.leu.2404980 CrossRefPubMed

103.

Y. Tong, Y.Y. Liu, L.S. You, W.B. Qian, Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacol. Sin. 33, 542–550 (2012). doi:10.1038/aps.2011.192 CrossRefPubMedPubMedCentral

104.

C. Recher, O. Beyne-Rauzy, C. Demur, G. Chicanne, C. Dos Santos, V.M. Mas, D. Benzaquen, G. Laurent, F. Huguet, B. Payrastre, Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105, 2527–2534 (2005). doi:10.1182/blood-2004-06-2494 CrossRefPubMed

105.

Q. Xu, J.E. Thompson, M. Carroll, mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106, 4261–4268 (2005). doi:10.1182/blood-2004-11-4468 CrossRefPubMedPubMedCentral

106.

F. Chiarini, A. Lonetti, G. Teti, E. Orsini, D. Bressanin, A. Cappellini, F. Ricci, P.L. Tazzari, A. Ognibene, M. Falconi, P. Pagliaro, I. Iacobucci, G. Martinelli, S. Amadori, J.A. McCubrey, A.M. Martelli, A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget 3, 1615–1628 (2012)CrossRefPubMedPubMedCentral

107.

D.C. Hassane, S. Sen, M. Minhajuddin, R.M. Rossi, C.A. Corbett, M. Balys, L. Wei, P.A. Crooks, M.L. Guzman, C.T. Jordan, Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 116, 5983–5990 (2010). doi:10.1182/blood-2010-04-278044 CrossRefPubMed

108.

K. Meja, C. Stengel, R. Sellar, D. Huszar, B.R. Davies, R.E. Gale, D.C. Linch, A. Khwaja, PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br. J. Haematol. 167, 69–79 (2014). doi:10.1111/bjh.13013 CrossRefPubMed

109.

F. Pellicano, M.T. Scott, G.V. Helgason, L.E. Hopcroft, E.K. Allan, M. Aspinall-O’Dea, M. Copland, A. Pierce, B.J. Huntly, A.D. Whetton, T.L. Holyoake, The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells 32, 2324–2337 (2014). doi:10.1002/stem.1748 CrossRefPubMedPubMedCentral

110.

N. Chapuis, J. Tamburini, A.S. Green, C. Vignon, V. Bardet, A. Neyret, M. Pannetier, L. Willems, S. Park, A. Macone, S.M. Maira, N. Ifrah, F. Dreyfus, O. Herault, C. Lacombe, P. Mayeux, D. Bouscary, Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin. Cancer Res. 16, 5424–5435 (2010). doi:10.1158/1078-0432.CCR-10-1102 CrossRefPubMed

111.

X. Ding, F. Li, J. McKnight, C. Schmidt, K. Strooisma, H. Shimizu, K. Faber, J.A. Ware, B. Dean, A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. J. Pharm. Biomed. Anal. 100, 150–156 (2014). doi:10.1016/j.jpba.2014.08.001 CrossRefPubMed

112.

P. Yu, A.D. Laird, X. Du, J. Wu, K.A. Won, K. Yamaguchi, P.P. Hsu, F. Qian, C.T. Jaeger, W. Zhang, C.A. Buhr, P. Shen, W. Abulafia, J. Chen, J. Young, A. Plonowski, F.M. Yakes, F. Chu, M. Lee, F. Bentzien, S.T. Lam, S. Dale, D.J. Matthews, P. Lamb, P. Foster, Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol. Cancer Ther. 13, 1078–1091 (2014). doi:10.1158/1535-7163.MCT-13-0709 CrossRefPubMed

113.

Z. Tothova, D.G. Gilliland, FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 1, 140–152 (2007). doi:10.1016/j.stem.2007.07.017 CrossRefPubMed

114.

K. Ito, A. Hirao, F. Arai, K. Takubo, S. Matsuoka, K. Miyamoto, M. Ohmura, K. Naka, K. Hosokawa, Y. Ikeda, T. Suda, Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med. 12, 446–451 (2006). doi:10.1038/nm1388 CrossRefPubMed

115.

F. Zhou, Q. Shen, F.X. Claret, Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. J. Leukoc. Biol. 94, 423–429 (2013). doi:10.1189/jlb.0113006 CrossRefPubMedPubMedCentral

116.

M. Nieborowska-Skorska, P.K. Kopinski, R. Ray, G. Hoser, D. Ngaba, S. Flis, K. Cramer, M.M. Reddy, M. Koptyra, T. Penserga, E. Glodkowska-Mrowka, E. Bolton, T.L. Holyoake, C.J. Eaves, S. Cerny-Reiterer, P. Valent, A. Hochhaus, T.P. Hughes, H. van der Kuip, M. Sattler, W. Wiktor-Jedrzejczak, C. Richardson, A. Dorrance, T. Stoklosa, D.A. Williams, T. Skorski, Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 119, 4253–4263 (2012). doi:10.1182/blood-2011-10-385658 CrossRefPubMedPubMedCentral

117.

S. Pei, M. Minhajuddin, K.P. Callahan, M. Balys, J.M. Ashton, S.J. Neering, E.D. Lagadinou, C. Corbett, H. Ye, J.L. Liesveld, K.M. O’Dwyer, Z. Li, L. Shi, P. Greninger, J. Settleman, C. Benes, F.K. Hagen, J. Munger, P.A. Crooks, M.W. Becker, C.T. Jordan, Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J. Biol. Chem. 288, 33542–33558 (2013). doi:10.1074/jbc.M113.511170 CrossRefPubMedPubMedCentral

118.

X. Chen, X. Shi, C. Zhao, X. Li, X. Lan, S. Liu, H. Huang, N. Liu, S. Liao, D. Zang, W. Song, Q. Liu, B.Z. Carter, Q.P. Dou, X. Wang, J. Liu, Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget 5, 9118–9132 (2014)CrossRefPubMedPubMedCentral

119.

Y. Du, Y. Xia, X. Pan, Z. Chen, A. Wang, K. Wang, J. Li, J. Zhang, Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling. Antioxid. Redox Signal. 20, 1866–1880 (2014). doi:10.1089/ars.2012.4935 CrossRefPubMedPubMedCentral

120.

K. Moulick, J.H. Ahn, H. Zong, A. Rodina, L. Cerchietti, E.M. Gomes DaGama, E. Caldas-Lopes, K. Beebe, F. Perna, K. Hatzi, L.P. Vu, X. Zhao, D. Zatorska, T. Taldone, P. Smith-Jones, M. Alpaugh, S.S. Gross, N. Pillarsetty, T. Ku, J.S. Lewis, S.M. Larson, R. Levine, H. Erdjument-Bromage, M.L. Guzman, S.D. Nimer, A. Melnick, L. Neckers, G. Chiosis, Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat. Chem. Biol. 7, 818–826 (2011). doi:10.1038/nchembio.670 CrossRefPubMedPubMedCentral

121.

P. Flandrin, D. Guyotat, A. Duval, J. Cornillon, E. Tavernier, N. Nadal, L. Campos, Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones 13, 357–364 (2008). doi:10.1007/s12192-008-0035-3 CrossRefPubMedPubMedCentral

122.

H. Reikvam, K.J. Hatfield, E. Ersvaer, R. Hovland, J. Skavland, B.T. Gjertsen, K. Petersen, O. Bruserud, Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention. Br. J. Haematol. 156, 468–480 (2012). doi:10.1111/j.1365-2141.2011.08960.x CrossRefPubMed

123.

M. Zackova, D. Mouckova, T. Lopotova, Z. Ondrackova, H. Klamova, J. Moravcova, Hsp90 - a potential prognostic marker in CML. Blood Cells Mol. Dis. 50, 184–189 (2013). doi:10.1016/j.bcmd.2012.11.002 CrossRefPubMed

124.

W. Yu, Q. Rao, M. Wang, Z. Tian, D. Lin, X. Liu, J. Wang, The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. Leuk. Res. 30, 575–582 (2006). doi:10.1016/j.leukres.2005.08.028

125.

J.E. Lancet, I. Gojo, M. Burton, M. Quinn, S.M. Tighe, K. Kersey, Z. Zhong, M.X. Albitar, K. Bhalla, A.L. Hannah, M.R. Baer, Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24, 699–705 (2010). doi:10.1038/leu.2009.292 CrossRefPubMed

126.

C. Gallerne, A. Prola, C. Lemaire, Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim. Biophys. Acta 1833, 1356–1366 (2013). doi:10.1016/j.bbamcr.2013.02.014 CrossRefPubMed

127.

S.R. Ambati, E.C. Lopes, K. Kosugi, U. Mony, A. Zehir, S.K. Shah, T. Taldone, A.L. Moreira, P.A. Meyers, G. Chiosis, M.A. Moore, Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Mol. Oncol. 8, 323–336 (2014). doi:10.1016/j.molonc.2013.12.005 CrossRefPubMed

128.

H. Zong, A. Gozman, E. Caldas-Lopes, T. Taldone, E. Sturgill, S. Brennan, S.O. Ochiana, E.M. Gomes-DaGama, S. Sen, A. Rodina, J. Koren 3rd, M.W. Becker, C.M. Rudin, A. Melnick, R.L. Levine, G.J. Roboz, S.D. Nimer, G. Chiosis, M.L. Guzman, A hyperactive signalosome in acute myeloid leukemia drives addiction to a tumor-specific Hsp90 species. Cell Rep. 13, 2159–2173 (2015). doi:10.1016/j.celrep.2015.10.073 CrossRefPubMedPubMedCentral

129.

C. Hurtz, K. Hatzi, L. Cerchietti, M. Braig, E. Park, Y.M. Kim, S. Herzog, P. Ramezani-Rad, H. Jumaa, M.C. Muller, W.K. Hofmann, A. Hochhaus, B.H. Ye, A. Agarwal, B.J. Druker, N.P. Shah, A.M. Melnick, M. Muschen, BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J. Exp. Med. 208, 2163–2174 (2011). doi:10.1084/jem.20110304 CrossRefPubMedPubMedCentral

130.

J.M. Polo, T. Dell’Oso, S.M. Ranuncolo, L. Cerchietti, D. Beck, G.F. Da Silva, G.G. Prive, J.D. Licht, A. Melnick, Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat. Med. 10, 1329–1335 (2004). doi:10.1038/nm1134 CrossRefPubMed

131.

C. Duy, J.J. Yu, R. Nahar, S. Swaminathan, S.M. Kweon, J.M. Polo, E. Valls, L. Klemm, S. Shojaee, L. Cerchietti, W. Schuh, H.M. Jack, C. Hurtz, P. Ramezani-Rad, S. Herzog, H. Jumaa, H.P. Koeffler, I.M. de Alboran, A.M. Melnick, B.H. Ye, M. Muschen, BCL6 is critical for the development of a diverse primary B cell repertoire. J. Exp. Med. 207, 1209–1221 (2010). doi:10.1084/jem.20091299 CrossRefPubMedPubMedCentral

132.

B. Sumithra, U. Saxena, A.B. Das, Alternative splicing within the Wnt signaling pathway: role in cancer development. Cell. Oncol. (Dordr) 39, 1–13 (2016). doi:10.1007/s13402-015-0266-0 CrossRef

133.

A.E. Abrahamsson, I. Geron, J. Gotlib, K.H. Dao, C.F. Barroga, I.G. Newton, F.J. Giles, J. Durocher, R.S. Creusot, M. Karimi, C. Jones, J.L. Zehnder, A. Keating, R.S. Negrin, I.L. Weissman, C.H. Jamieson, Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. U. S. A. 106, 3925–3929 (2009). doi:10.1073/pnas.0900189106 CrossRefPubMedPubMedCentral

134.

N.M. Ghahhari, S. Babashah, Interplay between microRNAs and WNT/beta-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur. J. Cancer 51, 1638–1649 (2015). doi:10.1016/j.ejca.2015.04.021 CrossRefPubMed

135.

J.P. Radich, H. Dai, M. Mao, V. Oehler, J. Schelter, B. Druker, C. Sawyers, N. Shah, W. Stock, C.L. Willman, S. Friend, P.S. Linsley, Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 103, 2794–2799 (2006). doi:10.1073/pnas.0510423103 CrossRefPubMedPubMedCentral

136.

A.M. Coluccia, A. Vacca, M. Dunach, L. Mologni, S. Redaelli, V.H. Bustos, D. Benati, L.A. Pinna, C. Gambacorti-Passerini, Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 26, 1456–1466 (2007). doi:10.1038/sj.emboj.7601485 CrossRefPubMedPubMedCentral

137.

L. Wang, L.S. You, W.M. Ni, Q.L. Ma, Y. Tong, L.P. Mao, J.J. Qian, J. Jin, beta-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia. Leuk. Res. 37, 1329–1340 (2013). doi:10.1016/j.leukres.2013.06.023 CrossRefPubMed

138.

A. Hamad, Z. Sahli, M. El Sabban, M. Mouteirik, R. Nasr, Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. Stem Cells Int. 2013, 724360 (2013). doi:10.1155/2013/724360 CrossRefPubMedPubMedCentral

139.

J. Yeung, M.T. Esposito, A. Gandillet, B.B. Zeisig, E. Griessinger, D. Bonnet, C.W. So, beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18, 606–618 (2010). doi:10.1016/j.ccr.2010.10.032 CrossRefPubMed

140.

S. Song, T. Christova, S. Perusini, S. Alizadeh, R.Y. Bao, B.W. Miller, R. Hurren, Y. Jitkova, M. Gronda, M. Isaac, B. Joseph, R. Subramaniam, A. Aman, A. Chau, D.E. Hogge, S.J. Weir, J. Kasper, A.D. Schimmer, R. Al-awar, J.L. Wrana, L. Attisano, Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res. 71, 7628–7639 (2011). doi:10.1158/0008-5472.CAN-11-2745 CrossRefPubMed

141.

A. Gandillet, S. Park, F. Lassailly, E. Griessinger, J. Vargaftig, A. Filby, T.A. Lister, D. Bonnet, Heterogeneous sensitivity of human acute myeloid leukemia to beta-catenin down-modulation. Leukemia 25, 770–780 (2011). doi:10.1038/leu.2011.17 CrossRefPubMedPubMedCentral

142.

E.C. Hales, J.W. Taub, L.H. Matherly, New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of gamma-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell. Signal. 26, 149–161 (2014). doi:10.1016/j.cellsig.2013.09.021 CrossRefPubMed

143.

F. Damm, B. Markus, F. Thol, M. Morgan, G. Gohring, B. Schlegelberger, J. Krauter, M. Heuser, O.A. Bernard, A. Ganser, TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns. Genes Chromosomes Cancer 53, 824–832 (2014). doi:10.1002/gcc.22191 CrossRefPubMed

144.

C. Lobry, P. Ntziachristos, D. Ndiaye-Lobry, P. Oh, L. Cimmino, N. Zhu, E. Araldi, W. Hu, J. Freund, O. Abdel-Wahab, S. Ibrahim, D. Skokos, S.A. Armstrong, R.L. Levine, C.Y. Park, I. Aifantis, Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J. Exp. Med. 210, 301–319 (2013). doi:10.1084/jem.20121484 CrossRefPubMedPubMedCentral

145.

C. Dierks, R. Beigi, G.R. Guo, K. Zirlik, M.R. Stegert, P. Manley, C. Trussell, A. Schmitt-Graeff, K. Landwerlin, H. Veelken, M. Warmuth, Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14, 238–249 (2008). doi:10.1016/j.ccr.2008.08.003 CrossRefPubMed

146.

M.Y. Konopleva, C.T. Jordan, Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol. 29, 591–599 (2011). doi:10.1200/JCO.2010.31.0904 CrossRefPubMedPubMedCentral

147.

L. Jin, Y. Tabe, S. Konoplev, Y. Xu, C.E. Leysath, H. Lu, S. Kimura, A. Ohsaka, M.B. Rios, L. Calvert, H. Kantarjian, M. Andreeff, M. Konopleva, CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol. Cancer Ther. 7, 48–58 (2008). doi:10.1158/1535-7163.MCT-07-0042 CrossRefPubMed

148.

L. Brault, A. Rovo, S. Decker, C. Dierks, A. Tzankov, J. Schwaller, CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia. Leukemia 28, 566–576 (2014). doi:10.1038/leu.2013.201 CrossRefPubMed

149.

E. Weisberg, A.K. Azab, P.W. Manley, A.L. Kung, A.L. Christie, R. Bronson, I.M. Ghobrial, J.D. Griffin, Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 26, 985–990 (2012). doi:10.1038/leu.2011.360 CrossRefPubMed

150.

S. Tavor, I. Petit, S. Porozov, A. Avigdor, A. Dar, L. Leider-Trejo, N. Shemtov, V. Deutsch, E. Naparstek, A. Nagler, T. Lapidot, CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 64, 2817–2824 (2004)CrossRefPubMed

151.

Y. Wang, Y. Liu, S.N. Malek, P. Zheng, Y. Liu, Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 8, 399–411 (2011). doi:10.1016/j.stem.2011.02.006 CrossRefPubMedPubMedCentral

152.

M. Shahjahani, J. Mohammadiasl, F. Noroozi, M. Seghatoleslami, S. Shahrabi, F. Saba, N. Saki, Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis. Cell. Oncol. 38, 93–109 (2015). doi:10.1007/s13402-014-0215-3 CrossRef

153.

A. Chávez-González, S. Avilés-Vázquez, D. Moreno-Lorenzana, H. Mayani, in Stem cell biology in normal life and diseases, ed. by K. Alimoghaddam (InTech, 2013)

154.

J.M. Goldman, How I treat chronic myeloid leukemia in the imatinib era. Blood 110, 2828–2837 (2007). doi:10.1182/blood-2007-04-038943 CrossRefPubMed

155.

R. Bhatia, M. Holtz, N. Niu, R. Gray, D.S. Snyder, C.L. Sawyers, D.A. Arber, M.L. Slovak, S.J. Forman, Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701–4707 (2003). doi:10.1182/blood-2002-09-2780 CrossRefPubMed

156.

M. Copland, A. Hamilton, L.J. Elrick, J.W. Baird, E.K. Allan, N. Jordanides, M. Barow, J.C. Mountford, T.L. Holyoake, Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107, 4532–4539 (2006). doi:10.1182/blood-2005-07-2947 CrossRefPubMed

157.

H.G. Jorgensen, E.K. Allan, N.E. Jordanides, J.C. Mountford, T.L. Holyoake, Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109, 4016–4019 (2007). doi:10.1182/blood-2006-11-057521 CrossRefPubMed

158.

A. Hamilton, G.V. Helgason, M. Schemionek, B. Zhang, S. Myssina, E.K. Allan, F.E. Nicolini, C. Muller-Tidow, R. Bhatia, V.G. Brunton, S. Koschmieder, T.L. Holyoake, Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501–1510 (2012). doi:10.1182/blood-2010-12-326843 CrossRefPubMedPubMedCentral

159.

J. Bertacchini, N. Ketabchi, L. Mediani, S. Capitani, S. Marmiroli, N. Saki, Inhibition of Ras-mediated signaling pathways in CML stem cells. Cell. Oncol. 38, 407–418 (2015). doi:10.1007/s13402-015-0248-2 CrossRef

160.

J.H. Black, J.A. McCubrey, M.C. Willingham, J. Ramage, D.E. Hogge, A.E. Frankel, Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia 17, 155–159 (2003). doi:10.1038/sj.leu.2402744 CrossRefPubMed

161.

T. Cierpicki, J. Grembecka, Challenges and opportunities in targeting the menin-MLL interaction. Future Med. Chem. 6, 447–462 (2014). doi:10.4155/fmc.13.214 CrossRefPubMedPubMedCentral

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer

Abstract

Background

Conclusions

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma

Collective cell migration of thyroid carcinoma cells: a beneficial ability to override unfavourable substrates

Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma

Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine

Erufosine increases RhoB expression in oral squamous carcinoma cells independent of its tumor suppressive mode of action - a short report

Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien